English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

IFN- γ  has been used in the treatment of IL-12R β 1 deficiency patients with disseminated BCG infection (BCGosis), but the optimal dose to reach efficacy is not clear. We used IFN- γ  in the treatment of a 2.7-year-old patient with IL-12R β 1 deficiency and refractory BCG-osis. IFN γ  was started at a dose of 50  μ g/m 2  3 times per week. The dose was upgraded to 100 mcg/m 2  after 3 months, then to 200 mcg/m 2  6 months afterwards. Serum mycobactericidal activity and lymphocytes number and function were evaluated throughout the study. There was no clinical response to IFN- γ  with 50 or 100  μ g/m 2  doses. However, there was some response to the 200  μ g/m 2  dose with no additional adverse effects. The serum mycobactericidal activity was not significantly different during the whole treatment period. Lymphocytes proliferation in response to PHA was significantly higher after 3 months of using the highest dose as compared to the lowest dose. The tuberculin skin test reaction remained persistently negative. We conclude that in a patient with IL-12R β 1 deficiency, IFN- γ  at a dose of 200  μ g/m 2 , but not at lower dosages, was found to have a noticeable clinical effect with no additional adverse effects.

Treatment of Disseminated Mycobacterial Infection with High-Dose IFN-γin a Patient with IL-12Rβ1 Deficiency